@article{8a12d7e240904014a0eee4840bf250a1,
title = "Role of 18F-FDG PET/CT in the diagnosis of cardiovascular implantable electronic device infections: A meta-analysis",
abstract = "Objective: We performed a meta-analysis evaluating the use of fluorine-18-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET)/computed tomography (CT) in the diagnosis of cardiovascular implantable electronic device (CIED) infections. Background: PET/CT may be helpful in the diagnosis of CIED infection, particularly in patients with the absence of localizing signs or definitive echocardiographic findings. Methods: PubMed, Embase, Cochrane library, CINAHL, Web of Knowledge, and www.clinicaltrials.gov from January 1990 to April 2017 were searched for studies evaluating the accuracy of PET/CT in the diagnosis of CIED infections. Results: Overall, 14 studies involving 492 patients were included in the meta-analysis. The pooled sensitivity of PET/CT for diagnosis of CIED infection was 83% (95% CI 78%-86%) and the pooled specificity was 89% (95% CI 84%-94%). PET/CT demonstrated a higher sensitivity of 96% (95% CI 86%-99%) and specificity of 97% (95% CI 86%-99%) for diagnosis of pocket infections. Diagnostic accuracy for lead infections or CIED-IE was lower with pooled sensitivity of 76% (95% CI 65%-85%) and specificity of 83% (95% CI 72%-90%). Conclusion: Use of PET/CT in the evaluation of CIED infection has both a high sensitivity (83%) and specificity (89%) and deserves consideration in the management of selected patients with suspected CIED infections.",
keywords = "CIED, PET, imaging, infection, meta-analysis",
author = "Maryam Mahmood and Kendi, {Ayse Tuba} and Saira Farid and Saira Ajmal and Johnson, {Geoffrey B.} and Baddour, {Larry M.} and Panithaya Chareonthaitawee and Friedman, {Paul A.} and Sohail, {M. Rizwan}",
note = "Funding Information: L.M.B.: UpToDate, Inc. Royalty payments for authorship duties. M.R.S.: Honoraria/Consulting fee: Medtronic Inc., Spectranetics, and Boston Scientific Corporation (All \US$10K). Research Grant: Medtronic Inc. P.A.F.: Research support from St. Jude Medical; owning intellectual property rights with Aegis Medical, NeoChord, Preventice, and Sorin; and receiving speaker or consultant fees from Medtronic Inc. and LeadEx. G.B.J.: Research support from Pfizer, and Medtronic Inc. P.C., M.M., S.A., S.F., and A.T.K.: No relationship with industry. Funding Information: L.M.B.: UpToDate, Inc. Royalty payments for authorship duties. M.R.S.: Honoraria/Consulting fee: Medtronic Inc., Spectranetics, and Boston Scientific Corporation (All <US$10K). Research Grant: Medtronic Inc. P.A.F.: Research support from St. Jude Medical; owning intellectual property rights with Aegis Medical, NeoChord, Preventice, and Sorin; and receiving speaker or consultant fees from Medtronic Inc. and LeadEx. G.B.J.: Research support from Pfizer, and Medtronic Inc. P.C., M.M., S.A., S.F., and A.T.K.: No relationship with industry. The authors have indicated that they have no financial conflict of interest. Publisher Copyright: {\textcopyright} 2017, American Society of Nuclear Cardiology. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
month = jun,
day = "15",
doi = "10.1007/s12350-017-1063-0",
language = "English (US)",
volume = "26",
pages = "958--970",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
number = "3",
}